Cognition Therapeutics Leads in Innovative Alzheimer's Research
Cognition Therapeutics, Inc. (NASDAQ: CGTX) is making significant strides in the field of neurodegenerative diseases. Recently, the company’s VP of Research, Dr. Mary Hamby, announced her participation in a pivotal workshop focused on precision medicine at the Neuroimmunology Drug Development Summit. This workshop aims to enhance the methodologies used in screening participants for clinical trials. By optimizing participant selection, the goal is to ensure that those most likely to benefit from innovative treatments are included.
Insights from the SHINE Study
During the workshop, Dr. Hamby will share critical insights from Cognition’s Phase 2 SHINE study focusing on zervimesine (CT1812), a promising therapeutic candidate for adults suffering from mild-to-moderate Alzheimer’s disease. The SHINE study highlighted that participants with reduced levels of a specific protein, known as p-tau217, demonstrated a significantly positive response to zervimesine treatment. Those with lower p-tau217 levels outperformed their placebo counterparts, scoring 95% better on the ADAS-Cog 11 scale and 108% better on the MMSE scale.
The Role of Plasma p-tau217 in Treatment Personalization
Dr. Hamby emphasized the importance of plasma p-tau217 assays, not only as diagnostic tools but also as potential markers to identify Alzheimer’s patients who are likely to respond well to therapies targeting beta amyloid (A?). With a simple blood test, healthcare providers can leverage this information to tailor treatment strategies for their patients, leading to more personalized medical care.
Upcoming Neuroimmunology Summit Details
The Neuroimmunology Drug Development Summit, occurring from February 25-27, 2025, serves as a platform for industry leaders to collaborate and share innovative research findings. The workshop titled "Patient Stratification for Precision Medicine in Neuroscience" will be co-hosted by Dr. Hamby in collaboration with Jiri Aubrecht, who is the VP and head of clinical biomarkers at Prothena.
About Cognition Therapeutics, Inc.
Cognition Therapeutics, Inc. is at the forefront of developing innovative, small-molecule therapies targeting age-related degenerative disorders of the central nervous system. Their leading candidate, zervimesine (CT1812), is currently being investigated in various clinical programs, including pivotal studies focusing on Alzheimer's disease and dementias like Lewy body dementia. The company believes that zervimesine may effectively influence cellular pathways impacted by these disorders through its unique interaction with the sigma-2 receptor, a novel approach different from traditional treatment methods.
Contact Information
For further inquiries, Cognition Therapeutics can be reached at:
Email: info@cogrx.com
Frequently Asked Questions
What new approaches is Cognition Therapeutics taking in Alzheimer's research?
Cognition Therapeutics is participating in workshops to refine participant selection in clinical trials, enhancing the precision of their studies.
What were the results of the Phase 2 SHINE study?
Participants with lower p-tau217 levels showed a much better response to treatment with zervimesine, significantly outperforming those on placebo.
What is the significance of plasma p-tau217 assays?
These assays may help identify which Alzheimer's patients will benefit the most from specific therapies, enabling personalized treatment strategies.
When and where is the Neuroimmunology Drug Development Summit?
The summit is scheduled for February 25-27, 2025, in Boston, promoting collaboration in drug development.
How can I learn more about Cognition Therapeutics?
Visit the company’s official website for detailed information about their innovative therapies and research updates.
